Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

Colston E, Grasela D, Gardiner D, Bucy RP, Vakkalagadda B, Korman AJ, Lowy I.

PLoS One. 2018 Jun 7;13(6):e0198158. doi: 10.1371/journal.pone.0198158. eCollection 2018.

2.

Allospecific CD4(+) T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance.

Chai JG, Ratnasothy K, Bucy RP, Noelle RJ, Lechler R, Lombardi G.

Eur J Immunol. 2015 Jul;45(7):2017-27. doi: 10.1002/eji.201545455. Epub 2015 May 20.

3.

Enhanced auto-antibody production and Mott cell formation in FcμR-deficient autoimmune mice.

Honjo K, Kubagawa Y, Suzuki Y, Takagi M, Ohno H, Bucy RP, Izui S, Kubagawa H.

Int Immunol. 2014 Dec;26(12):659-72. doi: 10.1093/intimm/dxu070. Epub 2014 Jul 3.

4.

Antibody-mediated rejection of single class I MHC-disparate cardiac allografts.

Hattori Y, Bucy RP, Kubota Y, Baldwin WM 3rd, Fairchild RL.

Am J Transplant. 2012 Aug;12(8):2017-28. doi: 10.1111/j.1600-6143.2012.04073.x. Epub 2012 May 11.

5.

A simple technique for augmentation of axonal ingrowth into chondroitinase-treated acellular nerve grafts using nerve growth factor.

Ovalle F Jr, Patel A, Pollins A, de la Torre J, Vasconez L, Hunt TR 3rd, Bucy RP, Shack RB, Thayer WP.

Ann Plast Surg. 2012 May;68(5):518-24. doi: 10.1097/SAP.0b013e3182380974.

PMID:
22531407
6.

The potency of allospecific Tregs cells appears to correlate with T cell receptor functional avidity.

Tsang JY, Ratnasothy K, Li D, Chen Y, Bucy RP, Lau KF, Smyth L, Lombardi G, Lechler R, Tam PK.

Am J Transplant. 2011 Aug;11(8):1610-20. doi: 10.1111/j.1600-6143.2011.03650.x.

7.

Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.

Macatangay BJ, Zheng L, Rinaldo CR, Landay AL, Pollard RB, Pahwa S, Lederman MM, Bucy RP.

Clin Vaccine Immunol. 2010 Sep;17(9):1452-9. doi: 10.1128/CVI.00498-09. Epub 2010 Jul 14.

8.

Measurement of antiretroviral drugs in the lungs of HIV-infected patients.

Twigg HL, Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, Rominger H, Zheng L, Collman RG, Coombs RW, Bucy RP, Rezk NL, Kashuba AD.

HIV Ther. 2010 Mar 1;4(2):247-251.

9.

Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival.

Tanriver Y, Ratnasothy K, Bucy RP, Lombardi G, Lechler R.

J Immunol. 2010 Feb 15;184(4):1757-64. doi: 10.4049/jimmunol.0902987. Epub 2010 Jan 18.

10.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; AIDS Clinical Trials Group A5130 team.

Vaccine. 2009 Oct 9;27(43):6088-94. doi: 10.1016/j.vaccine.2009.05.016. Epub 2009 May 29.

11.

Preferential priming of alloreactive T cells with indirect reactivity.

Brennan TV, Jaigirdar A, Hoang V, Hayden T, Liu FC, Zaid H, Chang CK, Bucy RP, Tang Q, Kang SM.

Am J Transplant. 2009 Apr;9(4):709-18. doi: 10.1111/j.1600-6143.2009.02578.x.

12.

Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.

Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, Stauss HJ, Bucy RP, Lombardi G, Lechler R.

J Clin Invest. 2008 Nov;118(11):3619-28. doi: 10.1172/JCI33185. Epub 2008 Oct 9.

13.

CD8+ suppressor T cells resurrected.

Kapp JA, Bucy RP.

Hum Immunol. 2008 Nov;69(11):715-20. doi: 10.1016/j.humimm.2008.07.018. Epub 2008 Sep 24. Review.

PMID:
18817830
14.

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, Saag MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA; UAB Acute Infection, Early Disease Research Program (AIEDRP) Group.

AIDS. 2008 May 11;22(8):957-62. doi: 10.1097/QAD.0b013e3282fbd1da.

15.

Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects.

Twigg Iii HL, Weiden M, Valentine F, Schnizlein-Bick CT, Bassett R, Zheng L, Wheat J, Day RB, Rominger H, Collman RG, Fox L, Brizz B, Dragavon J, Coombs RW, Bucy RP; AIDS Clinical Trials Group Protocol 723 Team.

J Infect Dis. 2008 Jan 1;197(1):109-16. doi: 10.1086/523766.

PMID:
18171293
17.

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team.

Arch Intern Med. 2007 Mar 26;167(6):597-605.

PMID:
17389292
18.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R; Adult AIDS Clinical Trials Group A5024 Protocol Team.

J Infect Dis. 2006 Dec 15;194(12):1672-6. Epub 2006 Nov 8.

PMID:
17109338
19.
21.

Viral and cellular dynamics in HIV disease.

Bucy RP.

Curr HIV/AIDS Rep. 2004 Apr;1(1):40-6. Review.

PMID:
16091222
22.

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM.

Hum Gene Ther. 2005 Jan;16(1):91-100.

PMID:
15703492
23.

Activation and migration of allo-peptide specific TCR transgenic T cells in cardiac allograft rejection.

Honjo K, Xu XY, Kapp JA, Bucy RP.

Cell Immunol. 2004 Jul;230(1):44-55.

PMID:
15541718
24.
26.

Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.

Bartlett JA, Miralles GD, Sevin AD, Silberman M, Pruitt SK, Ottinger J, Gryszowska V, Fiscus SA, Bucy RP; ACTG 380 Study Team.

AIDS Res Hum Retroviruses. 2002 May 20;18(8):535-43.

PMID:
12036483
27.

Immune function in patients with rheumatoid arthritis treated with etanercept.

Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW.

Clin Immunol. 2002 Apr;103(1):13-21.

PMID:
11987981
28.

Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway.

Stephensen CB, Rasooly R, Jiang X, Ceddia MA, Weaver CT, Chandraratna RA, Bucy RP.

J Immunol. 2002 May 1;168(9):4495-503.

29.

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, Gonzalez CJ, Schnizlein-Bick CT, Evans T, Squires KE, Phair JP.

AIDS Res Hum Retroviruses. 2002 Jan 20;18(2):95-102.

PMID:
11839142
30.
31.

Viral and Cellular Dynamics in HIV Disease.

Bucy RP.

Curr Infect Dis Rep. 2001 Jun;3(3):295-301.

PMID:
11384561
32.

Quantitation of HIV-1 by real-time PCR with a unique fluorogenic probe.

Saha BK, Tian B, Bucy RP.

J Virol Methods. 2001 Apr;93(1-2):33-42.

PMID:
11311341
33.
34.

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.

Kilby JM, Goepfert PA, Miller AP, Gnann JW Jr, Sillers M, Saag MS, Bucy RP.

Ann Intern Med. 2000 Sep 19;133(6):435-8. Review.

PMID:
10975961
35.

Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR.

Hockett RD Jr, Saag MS, Kilby JM, Sfakianos G, Wakefield TB, Bucy RP.

J Virol Methods. 2000 Jun;87(1-2):1-12.

PMID:
10856747
36.

Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.

Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, Ferrari G, Ottinger J, Boeck A, Kloster AL, McLaughlin TM, Bleich KB, Ungerleider RM, Lyerly HK, Wilkinson WE, Rousseau FS, Heath-Chiozzi ME, Leonard JM, Haase AT, Shaw GM, Bucy RP, Douek DC, Koup RA, Haynes BF, Bolognesi DP, Weinhold KJ.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):403-13.

PMID:
10772526
37.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
38.

The Arthus reaction in rodents: species-specific requirement of complement.

Szalai AJ, Digerness SB, Agrawal A, Kearney JF, Bucy RP, Niwas S, Kilpatrick JM, Babu YS, Volanakis JE.

J Immunol. 2000 Jan 1;164(1):463-8.

39.

Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.

Derdeyn CA, Kilby JM, Miralles GD, Li LF, Sfakianos G, Saag MS, Hockett RD, Bucy RP.

J Infect Dis. 1999 Dec;180(6):1851-62.

PMID:
10558941
40.

Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.

Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, Kropf DA, Carroll WR, Peters GE, Bucy RP, Curiel DT, Krasnykh V.

Clin Cancer Res. 1999 Sep;5(9):2571-9.

41.

Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.

Derdeyn CA, Costello C, Kilby JM, Sfakianos G, Saag MS, Kaslow R, Bucy RP.

AIDS Res Hum Retroviruses. 1999 Aug 10;15(12):1063-71.

PMID:
10461826
42.

The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin.

Louro ID, McKie-Bell P, Gosnell H, Brindley BC, Bucy RP, Ruppert JM.

Cell Growth Differ. 1999 Jul;10(7):503-16.

43.

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP.

J Exp Med. 1999 May 17;189(10):1545-54.

44.

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM.

J Clin Invest. 1999 May 15;103(10):1391-8.

45.

Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection.

Bucy RP.

AIDS Res Hum Retroviruses. 1999 Feb 10;15(3):223-7. No abstract available.

PMID:
10052752
46.

Heterogeneity in the clonal T cell response. Implications for models of T cell activation and cytokine phenotype development.

Weaver CT, Saparov A, Kraus LA, Rogers WO, Hockett RD, Bucy RP.

Immunol Res. 1998;17(3):279-302. Review.

PMID:
9638473
47.

Quantitative assessment of inflammatory cytokine gene expression in chronic adult periodontitis.

Roberts FA, Hockett RD Jr, Bucy RP, Michalek SM.

Oral Microbiol Immunol. 1997 Dec;12(6):336-44.

PMID:
9573807
48.

Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.

Moreland LW, Haverty TP, Wacholtz MC, Knowles RW, Bucy RP, Heck LW Jr, Koopman WJ.

J Rheumatol. 1998 Feb;25(2):221-8.

PMID:
9489810
49.

Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.

Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS.

AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1533-7.

PMID:
9390753
50.

The effect of rhGH in vitro on donor-specific hyporesponsiveness in pediatric transplantation.

Benfield MR, Vail A, Waldo FB, Bucy RP, Kohaut EC.

Pediatr Transplant. 1997 Aug;1(1):90-7.

PMID:
10084793

Supplemental Content

Support Center